Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Subcutaneous epcoritamab in R/R B-cell non-Hodgkin lymphoma

Martin Hutchings • 18 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Non-Hodgkin Lymphoma Antibodies Epcoritamab

Martin Hutchings, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, discusses the results from a Phase I/II dose-escalation study investigating subcutaneous epcoritamab (CD3xCD20) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Additionally, Dr Hutchings outlines safety signals detected during the clinical trial. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Martin Hutchings

2:54
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
Martin Hutchings • 10 Dec 2023
3:58
Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS
Martin Hutchings • 10 Dec 2023
Bispecific antibodies in NHL
Krish Patel et al. • 17 Oct 2023
1:32
Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab
Martin Hutchings • 11 Dec 2022

Related Videos

3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
2:09
Using lineage tracing to define responding CAR T-cells in patients with LBCL
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals